OncLive Staff

Articles

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023

Dr Danish discusses barriers to using radiotherapy for the treatment of patients with metastatic lung and bone cancers; the novel capabilities of SCINTIX biology-guided technology; and how John Theurer Cancer Center plans to use this technology and help advance its role in the field of radiation oncology.

FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

August 3rd 2023

Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.

Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST

July 31st 2023

Dr Trent discusses the current role and significance of using MRD in gastrointestinal stromal tumor, current guidelines around mutation testing, and research seeking to expand the targeted therapy armamentarium.

Camidge and Abbott Discuss the Role of the Biotechnology Analyst in Drug Development

July 27th 2023

In this episode of ‘How This is Building Me,’ Drs Camidge and Abbott discuss the road from bench scientist to biotechnology analyst, rules and regulations in the industry, and more.

Advances in Early-Stage Breast Cancer Pull Biology and Biomarkers Into Focus

July 25th 2023

As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.

Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL

July 24th 2023

Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.

Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer

July 20th 2023

Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future implications of these findings, and the importance of continued investigation in this area.

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023

Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.

Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management

July 13th 2023

Dr Lunning sits down with Jeremy Abramson, MD, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.

FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

July 10th 2023

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer

July 6th 2023

Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer and findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease.

Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

July 3rd 2023

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023

June 29th 2023

Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.

Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer

June 26th 2023

In this episode of ‘How This is Building Me,’ Dr Camidge is rejoined by Dr Cetnar to discuss the good, the bad, and the ugly of the lung cancer data that were presented at the 2023 ASCO Annual Meeting.

Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care

June 22nd 2023

Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and the importance of connecting patients with a multidisciplinary team to provide necessary resources and care.

Investigators to Explore Potential of LP-300 With Chemo in Never Smokers With Advanced Lung Cancer

June 20th 2023

Joshua Eric Reuss, MD, discusses the enrollment criteria for the HARMONIC trial, the demonstrated safety and efficacy of LP-300, and potential benefits of the agent for never smokers with advanced non–small cell lung cancer.

Strides in GI Cancer Subsets Influence Advances

June 20th 2023

Tanios S. Bekaii-Saab, MD, highlights the unmet needs in GI malignancies and discusses how interdisciplinary meetings, such as the 20th Annual Meeting of the International Society of Gastrointestinal Oncology, provide the framework for disseminating information and driving innovative advances.

Reuss Reviews the Development of LP-300 in Advanced NSCLC

June 19th 2023

Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

June 12th 2023

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.